Top Page
Covalon Technologies
(COV)
Covalon Technologies (COV) vs. S&P 500 (SPY)
Covalon Technologies Business Overview & Revenue Model
Covalon Technologies Financial Statement Overview
| Breakdown | |||||
| TTM | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 34.67M | 31.17M | 26.60M | 18.15M | 19.56M | 25.80M | Gross Profit |
| 20.89M | 18.93M | 14.36M | 7.49M | 9.70M | 12.49M | EBIT |
| 4.27M | 2.15M | -4.49M | -9.14M | 838.34K | -6.09M | EBITDA |
| 5.98M | 3.14M | -3.49M | -8.11M | 1.54M | -6.63M | Net Income Common Stockholders |
| 4.73M | 2.67M | -4.46M | -9.66M | 23.48M | -6.95M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 1.83M | 16.75M | 8.79M | 14.06M | 22.95M | 3.51M | Total Assets |
| 13.23M | 31.81M | 24.90M | 30.38M | 40.58M | 34.70M | Total Debt |
| 0.00 | 901.67K | 1.56M | 2.17M | 2.59M | 20.90M | Net Debt |
| -1.83M | -15.85M | -7.23M | -11.89M | -20.36M | 17.40M | Total Liabilities |
| 2.90M | 4.30M | 6.11M | 6.15M | 7.21M | 25.59M | Stockholders Equity |
| 10.32M | 27.50M | 18.79M | 24.23M | 33.37M | 9.11M |
| Cash Flow | Free Cash Flow | ||||
| 2.99M | 3.06M | -4.50M | -9.08M | 443.71K | -4.40M | Operating Cash Flow |
| 3.50M | 3.47M | -3.18M | -7.99M | 621.37K | -4.03M | Investing Cash Flow |
| -384.12K | -281.63K | -81.02K | -843.02K | -278.53K | -370.41K | Financing Cash Flow |
| 5.01M | 4.97M | -2.16M | -2.19M | -8.25M | -1.75M |
Covalon Technologies Technical Analysis
Covalon Technologies Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | C$72.11M | 14.27 | 19.57% | ― | 38.28% | ― | |
65 Neutral | C$50.69M | 25.35 | 6.85% | ― | 2.72% | -47.79% | |
60 Neutral | $10.96B | 10.27 | -6.73% | 2.97% | 7.73% | -11.60% | |
43 Neutral | $60.50M | ― | -184.69% | ― | ― | 0.10% | |
33 Underperform | C$64.05M | ― | 248.46% | ― | ― | 32.71% | |
33 Underperform | C$50.90M | ― | 685.26% | ― | ― | -50.29% | |
25 Underperform | C$64.46M | ― | ― | -32.14% | -52.38% |
Covalon Technologies Earnings Call Summary
Covalon Technologies Corporate Events
Covalon Technologies Ltd. announced its participation in the 2025 Bloom Burton & Co. Healthcare Investor Conference, where CEO Brent Ashton will present the company’s mission to prevent complications and save lives in healthcare through innovative technologies. The presentation will highlight Covalon’s strong financial position and key growth drivers, emphasizing the company’s focus on delivering compassionate care solutions that improve patient outcomes and drive long-term value for stakeholders.
Spark’s Take on TSE:COV Stock
According to Spark, TipRanks’ AI Analyst, TSE:COV is a Outperform.
Covalon Technologies maintains a strong overall score due to impressive financial performance and strategic corporate events. While technical analysis presents challenges with downward momentum, the company’s valuation and positive earnings call sentiment support its potential for future growth. Continued focus on operational efficiency and strategic advancements will be crucial.
To see Spark’s full report on TSE:COV stock, click here.
Covalon Technologies Ltd. announced its participation in the Planet MicroCap Showcase: VEGAS 2025, highlighting its position as an undervalued, cash-rich, and profitable healthcare company in the microcap sector. The company, recognized as a top-performing organization, aims to attract US and international investors by showcasing its significant growth opportunities in the healthcare sector, driven by its advanced wound care and surgical products that address preventable complications, thereby improving patient outcomes and reducing unnecessary treatments.
Spark’s Take on TSE:COV Stock
According to Spark, TipRanks’ AI Analyst, TSE:COV is a Outperform.
Covalon Technologies’ stock is rated highly due to its strong financial health, marked by impressive revenue and profitability metrics, and strategic corporate advantages. The favorable valuation and positive earnings call sentiment further bolster its position, despite some technical analysis concerns. Continued focus on operational efficiency and strategic growth will be crucial for sustaining long-term performance.
To see Spark’s full report on TSE:COV stock, click here.
Covalon Technologies Ltd. has announced a favorable outcome from recent U.S. tariff decisions, as its Canadian-manufactured products are exempt from tariffs under the USMCA guidelines. This exemption allows Covalon to maintain competitive pricing and uninterrupted access to the U.S. market, positioning the company advantageously against competitors who face significant tariffs. As the largest advanced wound care collagen dressing manufacturer in North America, Covalon is set to capitalize on this strategic advantage, enhancing its market positioning and operational capabilities.
Covalon Technologies announced the successful voting results from its Fiscal 2024 Annual Meeting of Shareholders, where all items of business, including the election of the Board of Directors and the appointment of auditors, were approved by the requisite number of votes. This outcome reflects strong shareholder support and is expected to positively impact Covalon’s governance and operational strategies, reinforcing its position in the medical technologies industry.
Covalon Technologies Ltd. has announced its annual meeting of shareholders, scheduled for March 19, 2025, to be held virtually. The meeting will feature a presentation by the newly appointed CEO, Brent Ashton, followed by a Q&A session, allowing shareholders to engage and vote online, reflecting the company’s commitment to transparent and accessible governance.
Covalon Technologies Ltd. reported a strong start to fiscal 2025 with its first quarter results showcasing significant revenue and earnings growth, driven primarily by its US Medical Consumables business. The company achieved a 75% year-over-year revenue increase, and notable earnings improvements, positioning it favorably in the market. Recent achievements include recognition as a top company on the TSX Ventures and OTCQX, securing a new patent, and expanding its hospital customer base, indicating strong future prospects.
Covalon Technologies Ltd. has been recognized as a 2025 Top 50 Company by the TSX Venture Exchange, highlighting its strong performance over the past year. This accolade reflects Covalon’s dedication to creating value through its product portfolios and its commitment to expanding and strengthening investor relationships in North America and beyond.
Covalon Technologies Ltd. has announced it will release its first quarter fiscal 2025 financial results on February 21, 2025, before the market opens. The company will hold a conference call and webcast on the same day at 8:30am ET to discuss the results, allowing participants to ask questions. This announcement could impact the company’s operations and provide insights into its financial health, influencing stakeholders and investors.